Cervical cancer kills approximately 4,000 women in the U.S. each year. And about 85% of all cervical cancer cases occur in developing countries, where routine screening is not a standard of care. Currently, only a small percentage of American women receive the series of vaccinations- and physicians are definitely interested in increasing this number.
Gardasil and Cervarix, the two cervical cancer vaccines currently available, require three doses within a six-month period. But a vaccine that could be effective after only one dose is highly desirable. One dose, given during a yearly physical, would be a much easier ‘sell’ than a vaccine requiring two more follow-up visits. Vaccination would also be more affordable.
After looking at immune responses in women who had received one, two, or three doses of the vaccine, researchers found that even after only receiving one vaccine, lasting effects were seen. While long-term research is definitely needed to determine whether or not these effects are enough to be considered protective, it’s definitely looking promising that current vaccine recommendations may be able to be altered in a way that would be more efficient. Read more here: